The 'common' 4977 bp deletion in mitochondrial DNA (∆4977) is commonly used as an indicator of tissue deterioration in ageing and bioenergetic diseases. Deletion levels are normally measured by a serial dilution polymerase chain reaction (PCR) approach, where test reactions are compared with dilutions of control amplifications of DNA from a similar sized stable region of the mitochondrial genome. The end-point of this assay is the dilution that can just detect any PCR product; however, this is an inherently unstable measure. We constructed a chimaeric DNA construct that binds to both control and deletion primers with similar annealing properties. This was used in a competitive PCR assay to quantify ∆4977 in human testicular tissues that had been well-characterized using the serial dilution approach. We found the competitive assay to be highly replicable as it compares the PCR product of the construct with that of test DNA samples during the linear growth phase of the PCR reaction. Moreover, the serial dilution assay was shown to significantly overestimate the amounts of deleted mitochondrial DNA present. The assay promises to throw new light on the role of mitochondrial DNA deletions in tissue dysfunction and ageing, as such deletions can now be determined with high accuracy and repeatability and is much cheaper to apply than real-time fluorescent quantitative PCR.
Introduction
. Alternatively, aberrant embryos may lack adequate proteolytic mechanisms for eliminating the sperm mitochondria Mitochondria are semi-autonomous organelles dedicated to (St John et al., 2000) . We have shown that even normozoothe production of energy by oxidative phosphorylation and spermic men have significant levels of deletions in their semen, generally (but not exclusively) transmitted through the female probably arising as a result of oxidative stress (Cummins germline (Cummins, 1998) . While the sperm tail and mid et al., 1998) . There is also concern that technologies using piece normally enter the oocyte at fertilization (Ankel-Simons cytoplasmic transfer to 'rescue' poor oocytes or embryos might and Cummins, 1996) , the paternal mitochondria do not generate abnormal individuals through heteroplasmy (Barritt normally survive beyond the morula stage. This is a species Cummins, 2001b) , and the poor outcomes currently specific proteolytic mechanism mediated by ubiquitination of seen with cloning technology may also be based on aberrant the sperm mitochondria during spermatogenesis (Sutovsky nuclear-cytoplasmic cross-talk (Cummins, 2001a . Normally the paternal mitochondria do not Turning from reproduction, there is expanding recognition survive, except in unusual situations such as inter-specific of the importance of mitochondrial DNA (mtDNA) deletions hybrids (Kaneda et al., 1995) and artificial cytoplasmic and mutations in a range of non-Mendelian-inherited bioconstructs (Meirelles and Smith, 1997, 1998) . The onset of energetic diseases and in normal tissue ageing (Wallace intracytoplasmic sperm injection (ICSI) in human assisted et al., 1995; Ozawa, 1997) . To quantify general mitochondrial reproduction has led to concerns that this might lead to damage, most publications rely upon the detection of the iatrogenic induction of mitochondrial disease in offspring, 4977 bp 'common deletion' for convenience, as an unambiguthrough the injection of abnormal spermatozoa that might ous specific indicator of more general mtDNA damage (Zhang et al., 1996) . The deletion arises between tandem 13 bp repeat evade destruction (Cummins and Jequier, 1995 ; Houshmand sequences through an error in replication. The result is to using ABI Prism dRhodamine Terminator and a 310 Genetic Analyser bring two distant primer target sequences close enough to be (ABI, Melbourne, Australia). amplified by polymerase chain reaction (PCR). This gives a truncated product relative to the intact genome. This is then
Serial dilutions method
compared with a control sequence of similar size in a conserved DNA was extracted from human testicular tissue using standard region of the genome, by serial dilution of a DNA sample.
techniques and mtDNA was estimated using primers and conditions Comparison of the dilutions at which the control and deleted as described previously (Cummins et al., 1998). products become undetectable is assumed to be an estimate of the relative amounts in the original DNA (Soong and Competitive PCR Arnheim, 1996) .
A competitive PCR assay was carried out using a range of dilutions There are a number of theoretical and practical problems of the competitor construct in conjunction with a constant amount of with this approach, but it persists because of ease of use and mtDNA (or cloned control or deletion products). Thus, the assay is the lack of need for specialized equipment. Many groups a relative competitive assay as the amount of deleted mtDNA is validate their identification of the deletion using a shift-PCR compared with the amount of control DNA (Ahmed et al., 1999) .
approach (Zhang et al., 1996) but again the end-point (dilution The latter is a measure of the total amount of DNA in a sample. Two until product is no longer detectable) means that one is working sets of reactions were set up to measure the deletion in each sample:
at the least sensitive point of the PCR reaction. Recently we one to measure the amount of deletion product using deletion primers described a fluorescence-based single-step PCR assay for and the other to measure the amount of control product (total mtDNA) the equivalent (4834 bp) deletion in rat mtDNA based on using control primers.
competition with a hybrid sequence with binding sites for both Three-fold dilution series were carried out with the competitor construct and amplified in a PCR reaction using the following 5Ј control and deletion primers (Ahmed et al., 1999) . Here, we fluorescein-labelled primer sets (Gibco BRL, Melbourne, Australia):
report on a successful extension of this approach to human 
Materials and methods
Amplification was carried out in 20 µl volumes in 0.2 ml thinwalled tubes (Bresatac, South Australia, Australia), using 20 pmoles Construction of the competitor of each primer: 300 µmol/l dNTPs; 25 mmol/l MgCl 2 ; 0.7 units The primers listed below were used to amplify the control (predicted Tthϩ in 67 mmol/l Tris-HCl; 16.6 mmol/l (NH 4 ) 2 SO 4 ; 0.45% Triton size 532 bp) and the deletion (predicted size 244 bp) products from X-100 and 0.2 mg/ml gelatin (Biotech International, Western Australia, the human mitochondrial genome (Anderson et al., 1981) (excision Australia). Cycling was carried out on an Eppendorf Mastercycler. number: J01415) and to construct the competitor (Figure 1 ). The
The reaction was started with a denaturation step at 94°C for 5 min, control primer set encompasses the NADH subunit 1, and the deletion followed by 35 PCR cycles of 94°C for 45 s, 58°C for 45 s and 72°C primer set encompasses a part of the NADH subunit 5 and the for 1 min, then a final extension step of 5 min at 72°C. tRNA lysine .
On completion of amplification, the reaction products were The two amplified products were cloned separately into the separated on a 2.75% agarose gel in 1ϫ TAE buffer (0.4 M Tris pCR2.1 vector (Invitrogen, Melbourne, Australia). The heterologous acetate; 0.01 M EDTA, pH 8.3). The products were detected using a competitor was constructed by shortening the control construct by Molecular Dynamics Fluorimager SI on a high sensitivity setting at digesting the plasmid with the enzymes BsmI and HincII, then treating 650 volts and quantified using Imagequant (Molecular Dynamics, with T4 DNA polymerase I to convert the 5Ј overhang (generated Sydney, Australia). from BsmI) to a blunt end. The vector was then self-ligated and the The relative amount of control product compared with deletion resulting control fragment was shown to be 296 bp in length. The (Figure 1 ) was determined by plotting the log value of the quantity deletion fragment was amplified by PCR using the enzyme pfu of added competitor DNA (x axis) versus the log value (of the (Strategene, La Jolla, CA, USA) to give it blunt ends. The control fluorescent signals) of the target divided by the competitor (y axis). plasmid was then digested with StuI, de-phosphorylated with shrimp
Where y ϭ 0.0, the molar ratio of competitor and target are equal alkaline phosphatase and the blunt ended deletion fragment was and this is extrapolated to the x axis to determine the dilution of ligated in.
competitor at this point. A similar calculation can be performed for The whole competitor fragment, including the multiple cloning site both the control and deletion products. The use of the same competitor of the pCR2.1 vector, was then amplified using standard M13 forward for both the control and the deletion products means that the amount and reverse primers, digested with DdeI and Sau96I, and the ends of deletion present can be expressed as a percentage of the amount were treated with T4 DNA polymerase I, to convert the 3Ј overhangs of mtDNA present. to blunt ends. Digestion with BamHI and AvaI was then carried out
We determined that the competitor product amplifies in a linear on the fragments and the pCR2.1 vector. The fragments were then fashion relative to input DNA and can compete for the respective ligated into the vector and the final competitor in produces a 453 bp cloned control and deletion products in a linear fashion. The competitor fragment when amplified using the control primers, and a 165 bp construct, cloned control and deletion products were quantified using fragment with the deletion primers. This gives a product size difference Pico Green (Molecular Dynamics); hence the molar equivalent of the of 79 bp each between the competitor products and the normal cloned products could be determined. Quantification of the DNA product sizes expected when amplifying from human mtDNA. The identities of the final construct and all intermediates were confirmed samples allowed the amount of DNA to be added to the reaction to Figure 1 . Diagrammatic representation of the construction of the competitor molecule. The control polymerase chain reaction (PCR) product of 532 bp was cloned into pCR2.1, and an internal fragment was removed by digestion with HincII and BsmI followed by re-ligation. The 244 bp deletion product was cloned into the modified control product by digestion with StuI and ligation. The hybrid molecule was amplified by flanking primers in the vector and an internal fragment removed from the deletion product by digestion with DdeI and Sau96I, followed by re-ligation. The resulting product was cut with BamHI and AvaI and inserted into pCR2.1 to yield competitor-pCR2.1.
be judged and the appropriate dilutions of cloned control and deletion all primer sites remained intact during the cloning processes.
product to be added to the reaction.
Amplification of the cloned control, deletion and competitor
To compare the efficiency of the different primer sets, the cloned constructs with both sets of primers showed that the predicted deletion product was added to a known amount of cloned control size products accumulate in a linear manner, relative to the product so that it represented 0.1, 1, and 10% of the control product.
input sample (Figure 2 ).
These mixtures were used to construct a standard calibration curve It was evident, however, that the signal intensity from the that relates the output of the deletion curve to the output of the deleted primer set was higher than that with the normal primer control curve, when the percentage of the deletion is known in set with the individual cloned products when using equal molar the original mixture (Figure 3 ). Using this relationship, we tested the amounts of input DNA. This has been noted previously, and amount of deletion product in mtDNA samples from human testicular is one of the major limitations of the serial dilution method biopsies, where we had previously detected deletions using the serial (Soong and Arnheim, 1996) . Therefore, it was necessary to dilution method (Cummins et al., 1998) .
make an adjustment in calculating the amount of deletion in a sample, because when the molar ratios of the products were Results equal, they did not give the same signal intensity with the The construction of the competitor (Figure 1 ) was confirmed different primer sets. The converse was also true. When the by sequencing (data not shown). The final competitor was a signal was equal, the molar ratios of the different products were not equal, as when the same dilution series of competitor 453 bp length fragment in the pCR2.1 vector (Invitrogen), and Figure 2 . Determination of the linearity (on a log scale) of competition between (A) control product and (B) deletion product and competitor construct. Known amounts of either cloned normal or cloned deletion product were mixed with diluted competitor molecule. The x axis represents the logarithm value of the concentration of the competitor. In both A and B '0' on the x axis represents an absolute amount of 1.0 pg of competitor DNA. The y axis represents the logarithm of the ratio of fluorescent signal of the added target (either cloned control or deletion product) compared with the competitor. Insert in each case is a picture of the agarose gel from which the data was obtained. In both cases the competition was linear but it was evident that the fluorescent signal differed depending on which primer set was used.
was used for both products. Therefore we tested the competitor to see whether it would compete in a predictable manner with 2). In both cases, it was evident that the competition was
The competition observed was plotted for each mixture and a correction factor calculated for each dilution. The mean of this linear. However, it was also evident that, for the same amount correction factor was then used to standardize the results obtained of input competitor in either Figure 2A or B (x axis), a in the competitive assay, and the results are shown in Table I. substantially different signal ratio was apparent (y axis). Because the signal intensity differed between the primer sets, it was necessary to include a correction factor to calculate the of values. The competitive assay was then carried out for each percentage added and the data plotted ( Figure 3 and Table I ). actual amount of deleted product in a mixed population of mtDNAs.
Knowing the amount of deletion product added, we found that a correction factor of 2.7 was necessary: in other words the Cloned deletion product was added at 10, 1 and 0.1% of the cloned control product. This 100-fold difference was used molar ratio calculated for the control product must be multiplied by 2.7 to obtain the real ratio between control and deleted to ensure that the assay could be carried out over a wide range (Brierley et al., 1998) . One group (Moslemi et al., 1996) normal tissues (Ͻ1 in 10 000) proper evaluation requires an assay that is both quantitative and accurate at this extreme To calibrate the assay, known mixes containing the cloned control and deletion products were prepared, so that the deletion represented 0.1, 1 and range.
10% of the total products. The competitive assay was carried out and a
We found that the serial dilution method seriously overcorrection value calculated as outlined in the text. The actual amount of estimated the amount of the common deletion in testicular deletion calculated in mixes using this single correction value is shown. The variation shown is derived from three separate assays.
tissues when compared with our competitive assay. This is probably due to the following reasons. Firstly, the serial dilution approach assumes that an equal input of template yields an equal output of PCR product. This is clearly not the Table II . Comparison of the amount of common deletion determined by the serial dilution method and the method described here. Samples including case as originally recognized (Soong and Arnheim, 1996) and both nuclear and mitochondrial DNA were prepared as previously described as demonstrated with the results reported here and for rat for the serial dilution method (Cummins et al., 1998) . Figures in mtDNA (Ahmed et al., 1999) . This is because different primer parentheses give the exact amounts of mtDNA in terms of the amounts detected relative to the control mtDNA assayed sets give different outputs with the same template. In the data presented here, this was greater than a 10-fold difference with second reason for the inaccuracies with the serial dilution method is that the end-point is judged on the disappearance of a product, not on an actual value. This will inevitably lead product in a mixture. The correction factor comprises two to inaccurate values because the calculation is limited by the underlying elements: (i) the difference in intensity of the signal sensitivity of detection. In addition, with the serial dilution obtained between two different sets of primers when using method, it requires at least three dilution series to estimate the equal molar ratios of DNA; and (ii) the kinetics of competition amount of the deletion present. The first of these is to get an with the two primers sets. It was found that the factor remained estimate of how much total DNA there is present in a particular unchanged with increasing levels of deletion up to 100-fold.
preparation. The second step is to do a five-fold dilution series The competitive assay was then carried out on testicular and the third to do a two-fold dilution series. Each of these tissue DNA that had been tested previously using the serial steps is subject to the above limitations and thus errors become dilution method (Table II) . We found that the serial dilution multiplied exponentially. method can over-estimate the levels of deletions in some Our competitor method described here overcomes these samples by up to 1000-fold. The minimum quantity of limitations. Only one dilution series need be carried out and deleted mtDNA that was detected successfully was 0.00007 pg the assay can be standardized with known mixes of DNA. An (Table II) .
additional benefit of this is that samples can be compared with each directly, as the same competitor is used and its Discussion concentration is known. Therefore, the actual amounts of deleted molecules in a mixture can be calculated. Moreover, The advent of PCR allows the detection of mutations from small DNA samples in amounts not previously possible. This the competitor method described here can be standardized and the presence of any impurities or inhibitors in a sample readily is clearly of huge benefit in mutation detection where no quantitative analysis of the data is necessary, as the simple identified. While this approach has not completely solved the question of accurate quantification (as discussed above in the presence or absence of a band indicates the presence or absence of a mutation. However, with the case of the common 4977 need to apply a correction factor), it is far more economical than the 'gold standard' of real-time fluorescent quantitative bp deletion in mtDNA (∆4977), accurate quantitative analysis of the data is necessary, as it is generally assumed that PCR (Orlando et al., 1998; Taylor et al., 2000) . The process of age-acquired mtDNA mutations and tissues can tolerate up to a given threshold of deletion before dysfunction results (Shoffner and Wallace, 1990; Zhang et al., deletions is still poorly understood. Part of the problem has been that accurate assays, which can measure abnormal to 1996). The overall levels of individual mutations in muscle of aged subjects, for example, can be low on average but may normal ratios in the order of 1 in 10 000, have not been available. In this paper, we describe the construction of a be high in individual muscle fibres and related to the degree of impairment as measured by cytochrome C oxidase deficiency competitive quantitative PCR assay for the ∆4977 mtDNA
